Docetaxel (taxotere(R)) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer

By Le Chevalier T.   Monnier A.   Douillard J.Y.   Ruffie P.   Sun X.S.   Belli L.   Ibrahim N.   Bougon N.   Berille J.  

European Journal of Cancer, Vol. 34, Iss. 13, 1998-12 ,pp. : 2032-2036

Elsevier

Access to resources Recommend Favorite

Cost-Utility Analysis of Paclitaxel in Combination with Cisplatin for Patients with Advanced Ovarian Cancer

By Ortega A.   Dranitsaris G.   Sturgeon J.   Sutherland H.   Oza A.  

Gynecologic Oncology, Vol. 66, Iss. 3, 1997-09 ,pp. : 454-463

Elsevier

Access to resources Recommend Favorite

Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer

By Cooper Brenda   Radivoyevitch Tomas   Overmoyer Beth   Shenk Robert   Pham Huong   Samuels Judith   Parry Margaret   Silverman Paula  

Breast Cancer Research and Treatment, Vol. 97, Iss. 3, 2006-06 ,pp. : 311-318

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer

By Polee M.B.   Verweij J.   Siersema P.D.   Tilanus H.W.   Splinter T.A.W.   Stoter G.   Van der Gaast A.  

European Journal of Cancer, Vol. 38, Iss. 11, 2002-07 ,pp. : 1495-1500

Elsevier

Access to resources Recommend Favorite

Cisplatin-Paclitaxel-Cyclophosphamide with G-CSF in Primary Advanced Epithelial Ovarian Cancer

By Fanning J.   Colgrove M.   Phibbs G.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 97-100

Elsevier

Access to resources Recommend Favorite